Nektar Therapeutics (NASDAQ:NKTR) Insider Jonathan Zalevsky Sells 10,300 Shares

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) insider Jonathan Zalevsky sold 10,300 shares of the company's stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $1.01, for a total value of $10,403.00. Following the transaction, the insider now owns 316,604 shares of the company's stock, valued at approximately $319,770.04. The trade was a 3.15 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Jonathan Zalevsky also recently made the following trade(s):

• On Thursday, December 19th, Jonathan Zalevsky sold 51,115 shares of Nektar Therapeutics stock. The stock was sold at an average price of $0.94, for a total transaction of $48,048.10.

Nektar Therapeutics Stock Performance

Shares of NKTR stock traded down $0.09 during mid-day trading on Wednesday, hitting $0.78. 2,356,568 shares of the stock traded hands, compared to its average volume of 2,434,869. The firm has a market cap of $143.90 million, a price-to-earnings ratio of -0.93 and a beta of 0.58. The company's 50-day simple moving average is $0.91 and its 200-day simple moving average is $1.11. Nektar Therapeutics has a twelve month low of $0.65 and a twelve month high of $1.93.

Institutional Investors Weigh In On Nektar Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Two Sigma Securities LLC boosted its position in shares of Nektar Therapeutics by 56.3% during the 4th quarter. Two Sigma Securities LLC now owns 27,654 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 9,958 shares in the last quarter. Harvest Investment Services LLC bought a new stake in Nektar Therapeutics during the fourth quarter worth approximately $27,000. US Asset Management LLC acquired a new position in Nektar Therapeutics in the fourth quarter worth approximately $31,000. Valence8 US LP acquired a new position in Nektar Therapeutics in the third quarter worth approximately $34,000. Finally, Intech Investment Management LLC bought a new position in shares of Nektar Therapeutics in the third quarter valued at $41,000. 75.88% of the stock is currently owned by institutional investors.

Remove Ads

Wall Street Analyst Weigh In

Several research firms have commented on NKTR. Piper Sandler initiated coverage on shares of Nektar Therapeutics in a research report on Monday, November 4th. They issued an "overweight" rating and a $7.00 target price for the company. William Blair reaffirmed a "market perform" rating on shares of Nektar Therapeutics in a research note on Tuesday. B. Riley initiated coverage on Nektar Therapeutics in a research note on Wednesday, January 8th. They issued a "buy" rating and a $4.00 price target for the company. Finally, HC Wainwright reissued a "buy" rating and set a $6.50 price target on shares of Nektar Therapeutics in a report on Tuesday. Two equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $4.08.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.